We use cookies to analyze the performance of our website. If you continue to visit our website you are consenting to our use of cookies.

Yes No More Info

ICRC-Weyer To Boost Drug Safety Services For Investigator Trials

An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors.

‘A large amount of IITs are oncology trials which generally bear a lot of adverse events (AEs) and serious adverse events (SAEs)’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Many of these events are unrelated to the drug in question. The SAE review process can be a substantial administrative burden for trial sponsors. With our flexible and highly responsive Pharmacovigilance Services we are in a position to take over the entire drug safety reporting for them.’

In addition, ICRC-Weyer is able to handle the reporting of serious adverse drug reactions (ADRs) – adverse events that are directly related to the substance. All events can be transmitted electronically using an E2B*-compliant database.

*Guideline on clinical safety data management by the International Conference on Harmonisation (ICH)

We use cookies to analyze the performance of our website. If you continue to visit our website you are consenting to our use of cookies.

Yes No More Info